Results 11 to 20 of about 260,030 (390)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Cancers, 2021
Activating mutations in KRAS are present in 25% of human cancers. When mutated, the KRAS protein becomes constitutively active, stimulating various effector pathways and leading to the deregulation of key cellular processes, including the suppression of apoptosis and enhancement of proliferation.
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Hiromichi Ebi   +3 more
openaire   +4 more sources

Kras in Organoids [PDF]

Cold Spring Harbor Perspectives in Medicine, 2018
Oncogenic Kras are genetic dependencies for the majority of pancreatic and colorectal adenocarcinomas; however, much remains to be understood regarding its tropism to these carcinomas. Recently developed organoid technology presents a more representative model culture system for pancreatic and colon epithelial tissues as well as better fostering the ...
David A. Tuveson, Derek K. Cheng
openaire   +3 more sources

Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine KrasG12D-induced skin carcinogenesis in vivo [PDF]

, 2010
Background The Ras and Notch signaling pathways are frequently activated during development to control many diverse cellular processes and are often dysregulated during tumorigenesis.
Barbara M. Grüner, Bence Sipos, Freddy Radtke, Hassan Nakhai, Jens T. Siveke, Joseph Alan Bauer, Lothar J. Strobl, Pawel K. Mazur, Roland M. Schmid, Ursula Zimber-Strobl   +9 more
core   +15 more sources

Targeting the MAPK Pathway in KRAS-Driven Tumors

Cancer Cell, 2020
Matthias Drosten, Mariano Barbacid
exaly   +2 more sources

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Science, 2023
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting.
C. Schulze, Kyle J. Seamon, Yulei Zhao, Y. C. Yang, J. Cregg, Dongsung Kim, A. Tomlinson, T. J. Choy, Zhican Wang, Ben Sang, Y. Pourfarjam, J. Lucas, Antonio Cuevas-Navarro, Carlos Ayala-Santos, Alberto Vides, Chuanchuan Li, Abby Marquez, Mengqi Zhong, Vidyasiri Vemulapalli, C. Weller, Andrea Gould, D. Whalen, Anthony Salvador, Anthony N Milin, Mae Saldajeno-Concar, Nuntana Dinglasan, Anqi Chen, James P. Evans, J. Knox, E. Koltun, Mallika Singh, R. Nichols, D. Wildes, Adrian L Gill, J. Smith, P. Lito   +35 more
semanticscholar   +1 more source

Remodeling KRAS [PDF]

Structure, 2017
Mutations in members of the RAS family of small GTPases have been associated with numerous human cancers. However, RAS family members are notoriously difficult to target. In this issue of Structure, Lu et al. (2017) examine the effects of two compounds with distinct chemical scaffolds on the structure and dynamics of an oncogenic KRAS mutant, thus ...
Daniel J, Deredge, Patrick L, Wintrode
openaire   +2 more sources

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Nature Network Boston, 2023
In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an encouraging overall response rate of 62.5% in patients with KRA S G12C -positive ...
Jayesh Desai, G. Alonso, Se Hyun Kim, A. Cervantes, T. Karasic, Laura Medina, E. Shacham-Shmueli, Rasha Cosman, A. Falcon, Eelke Gort, T. Guren, E. Massarelli, Wilson H Miller, Luis Paz-Ares, H. Prenen, A. Amatu, C. Cremolini, Tae Won Kim, Víctor Moreno, Sai-Hong Ignatius Ou, A. Passardi, A. Sacher, Armando Santoro, Rafal Stec, S. Ulahannan, K. Arbour, P. Lorusso, Jia Luo, Manish R. Patel, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, S. Royer-Joo, Julie Chang, Tomi Jun, N. Dharia, J. Schutzman, Sae-Won Han   +38 more
semanticscholar   +1 more source

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

New England Journal of Medicine, 2022
BACKGROUND KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.
J. Strickler, H. Satake, T. George, R. Yaeger, A. Hollebecque, I. Garrido-Laguna, M. Schuler, T. Burns, A. Coveler, G. Falchook, M. Vincent, Y. Sunakawa, L. Dahan, D. Bajor, S. Rha, C. Lemech, D. Juric, M. Rehn, G. Ngarmchamnanrith, Pegah Jafarinasabian, Q. Tran, D. Hong   +21 more
semanticscholar   +1 more source

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

Cancer Discovery, 2023
Molecular modifiers of KRAS G12C inhibitor (KRAS G12Ci) efficacy in advanced KRAS G12C-mutant NSCLC are poorly defined. In a large unbiased clinico-genomic analysis of 424 NSCLC patients, we identified and validated co-alterations in KEAP1, SMARCA4 and ...
M. Negrão, Haniel A Araujo, G. Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J. K. Hicks, M. Aldea, G. Minuti, J. Hines, J. Aredo, Michael J Dennis, T. Chakrabarti, S. Scott, P. Bironzo, M. Scheffler, P. Christopoulos, A. Stenzinger, J. Riess, So Yeon Kim, S. Goldberg, Mingjia Li, Qi Wang, Yun Qing, Y. Ni, Minh Truong Do, Richard Lee, B. Ricciuti, J. Alessi, Jing Wang, B. Resuli, L. Landi, Shu-Chi Tseng, M. Nishino, S. Digumarthy, W. Rinsurongkawong, Vadeerat Rinsurongkawong, A. Vaporciyan, G. Blumenschein, Jianjun Zhang, D. Owen, C. Blakely, G. Mountzios, C. Shu, C. Bestvina, M. Garassino, K. Marrone, J. Gray, S. Patel, A. Cummings, H. Wakelee, J. Wolf, G. Scagliotti, F. Cappuzzo, F. Barlesi, P. Patil, L. Drusbosky, D. Gibbons, F. Meric-Bernstam, J. Lee, J. Heymach, David S. Hong, R. Heist, M. Awad, F. Skoulidis   +65 more
semanticscholar   +1 more source

Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors

Science, 2023
Despite substantial advances in targeting mutant KRAS, tumor resistance to KRAS inhibitors (KRASi) remains a major barrier to progress. Here, we report proteostasis reprogramming as a key convergence point of multiple KRASi-resistance mechanisms ...
Xiangdong Lv, Xuan Lu, Jin Cao, Qin Luo, Yao Ding, Fanglue Peng, A. Pataer, Dong Lu, Dong Han, Eric Malmberg, Doug W. Chan, Xiaoran Wang, Sara R. Savage, Sufeng Mao, Jingjing Yu, Fei Peng, Liang Yan, Huan Meng, L. Maneix, Yumin Han, Yiwen Chen, W. Yao, Eric Chang, A. Catic, Xia Lin, George Miles, Pengxiang Huang, Zheng Sun, Bryan Burt, Huamin Wang, Jin Wang, Q. Yao, Bing Zhang, J. Roth, Bert W. O’Malley, M. Ellis, M. Rimawi, H. Ying, Xi Chen   +38 more
semanticscholar   +1 more source